Unearthing novel drug targets with robust data support and a deep understanding of biological processes remains a pivotal challenge in drug discovery. In this engaging webinar, distinguished speakers Aaron Mitchell and Rasmus Wernersson from ZS Associates will unveil a comprehensive method that significantly enhances target prediction performance through the integration of multiomics data, coupled with a data-driven, cell-type specific network biology approach.

This exclusive Q&A event invites you to ask anything about the world of predatory conferences to our expert speaker.

An incredible opportunity to ask the Chief Editor of Nature on how to get published in high-ranking journals.

Protein stability is one of the most important critical quality attributes for a new biological drug. Unstable or misfolded proteins are prone to aggregation and precipitation, which can lead to lower activity as well as increased immunogenicity. There has been a long-standing interest in renaturing unfolded, misfolded or precipitated proteins.

In this webinar, our expert speakers will demonstrate how thermal and pressure stress changed the structure and melting point of two model proteins and resulted in the discovery of different structural rearrangements.

They will then discuss a novel method for solubilizing and refolding proteins using hydrostatic pressure to generate proteins whose structure matches that of the native protein, as confirmed by microfluidic modulation spectroscopy.

Dr. Walker will discuss how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

In this webinar, we’ll discuss the challenges, risks and considerations involved in developing and using in-house residual testing solutions, and the benefits of using commercial kits for residual DNA testing, including shorter process development time, simplified regulatory acceptance and how they help to enable focus on process-specific development tasks.